| Literature DB >> 35345721 |
Haris Iftikhar1, Mavia Najam2, Khalid Bashir1.
Abstract
Herd behavior is a commonly used term to describe the conduct of different individuals in a group acting without using an individual thought process. The term was first coined by British surgeon Wilfred Trotter in 1914. This editorial will elaborate on how herd behavior has affected the healthcare industry and will include examples from the coronavirus disease 2019 (COVID-19) pandemic. Many interventions were introduced during the initial period of the pandemic, some of them later proved to be either incorrect or only beneficial to a selected group of patients. The nonmedical intervention included personal protective equipment (PPE), the establishment of fever clinics, and telemedicine. Some of these interventions were beneficial and will likely continue after the pandemic. The aim of this editorial is to highlight observed herd behavior in medical practice during pandemics and endorses the need for evaluation of evidence rigorously.Entities:
Keywords: covid-19; drugs; fever clinic; herd behavior; perspective; telemedicine; who
Year: 2022 PMID: 35345721 PMCID: PMC8942068 DOI: 10.7759/cureus.22472
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Summary of recommendations from WHO living guidelines (8th version) for or against the use of some drugs that were used during the COVID-19 pandemic.
WHO definitions for COVID-19 severity: Critical disease is characterized by sepsis, septic shock, acute respiratory distress syndrome, or other conditions due to which the patient needs noninvasive ventilation (NIV) or mechanical ventilation or vasopressor therapy. Severe disease is characterized by room air oxygen saturation <90%, presence of pneumonia on CXR, or signs of severe respiratory distress. Nonsevere or mild disease is characterized by the lack of the above findings for severe or critical disease [2]. IL-6: interleukin 6, CXR: chest X-ray.
| Recommendation Type | For/Against | Mild COVID-19 | Severe and Critical COVID-19 |
| Strong | For | x | Corticosteroids IL-6 receptor blockers (sarilumab or tocilizumab) baricitinib |
| Conditional | For | Sotrovimab | x |
| Conditional | For | Casirivimab and imdevimab | |
| Strong | Against | Convalescent plasma | x |
| Strong | Against | Lopinavir-ritonavir, hydroxychloroquine | |
| Conditional | Against | Corticosteroids | Ruxolitinib and tofacitinib convalescent plasma |
| Conditional | Against | Remdesivir, ivermectin | |